Puma Biotechnology Inc (NASDAQ:PBYI) gapped down before the market opened on Monday after BidaskClub downgraded the stock from a strong-buy rating to a buy rating. The stock had previously closed at $139.75, but opened at $127.20. Puma Biotechnology shares last traded at $103.00, with a volume of 5677100 shares trading hands.
Several other research analysts have also issued reports on PBYI. Citigroup Inc. increased their price target on shares of Puma Biotechnology from $156.00 to $164.00 and gave the stock a “buy” rating in a research report on Friday. Stifel Nicolaus reaffirmed a “buy” rating and set a $110.00 price objective (down previously from $118.00) on shares of Puma Biotechnology in a report on Thursday, August 10th. J P Morgan Chase & Co set a $105.00 price objective on shares of Puma Biotechnology and gave the stock a “buy” rating in a report on Wednesday, August 9th. Barclays PLC reaffirmed a “buy” rating and set a $122.00 price objective (up previously from $103.00) on shares of Puma Biotechnology in a report on Friday. Finally, Leerink Swann reaffirmed an “outperform” rating and set a $125.00 price objective on shares of Puma Biotechnology in a report on Wednesday, August 2nd. One research analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. Puma Biotechnology currently has a consensus rating of “Buy” and an average price target of $130.67.
In related news, SVP Richard Paul Bryce sold 15,000 shares of Puma Biotechnology stock in a transaction dated Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the senior vice president now owns 42,239 shares of the company’s stock, valued at approximately $5,068,680. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 22.70% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. boosted its holdings in Puma Biotechnology by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock valued at $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC boosted its holdings in Puma Biotechnology by 1.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,890,901 shares of the biopharmaceutical company’s stock valued at $226,435,000 after purchasing an additional 33,270 shares during the period. BlackRock Inc. boosted its holdings in Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock valued at $159,973,000 after purchasing an additional 86,924 shares during the period. Perceptive Advisors LLC boosted its holdings in Puma Biotechnology by 26.0% in the 3rd quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock valued at $110,627,000 after purchasing an additional 190,500 shares during the period. Finally, Franklin Resources Inc. bought a new stake in Puma Biotechnology in the 2nd quarter valued at about $50,134,000. 80.98% of the stock is owned by hedge funds and other institutional investors.
Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($2.50) by $0.43. The business had revenue of $6.10 million during the quarter, compared to the consensus estimate of $3.78 million. During the same period in the prior year, the firm earned ($1.11) EPS.
TRADEMARK VIOLATION NOTICE: This news story was reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another publication, it was illegally stolen and republished in violation of United States & international copyright & trademark law. The correct version of this news story can be viewed at https://weekherald.com/2017/11/14/puma-biotechnology-inc-pbyi-shares-gap-down-after-analyst-downgrade.html.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.